This inventor holds 1 USPTO granted patent. Top assignee: Onconova Therapeutics, Inc.. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012
Title: Innovations of Reddy M V Ramana in Cytotoxic Compounds
Introduction
Reddy M V Ramana is an accomplished inventor based in Blue Bell, Pennsylvania. He has made significant contributions to the field of medical treatments through his innovative work on activated cytotoxic compounds. His research focuses on developing targeted therapies for various mammalian disease conditions.
Latest Patents
Reddy M V Ramana holds a patent for "Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions." This patent describes activated cytotoxic compounds designed for attachment to targeting molecules, which include an activator, a spacer linker, a self-immolative linker, and a cytotoxic drug. The cytotoxic drugs mentioned in the patent include amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzenesulfonates, amino- and hydroxy-substituted styrylsulfonanilides, and substituted phenoxy- and phenylthio-styrylsulfone derivatives. The invention also outlines methods for treating various disease conditions using these compounds.
Career Highlights
Reddy M V Ramana is associated with Onconova Therapeutics, Inc., where he continues to advance his research in the field of targeted therapies. His work has the potential to significantly impact the treatment of diseases by improving the efficacy of cytotoxic drugs through targeted delivery.
Collaborations
Reddy has collaborated with notable colleagues, including Stanley Charles Bell and Glenn J Fegley, to further enhance the development of innovative therapeutic solutions.
Conclusion
Reddy M V Ramana's contributions to the field of activated cytotoxic compounds exemplify the importance of innovation in medical treatments. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the treatment of various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
